| タイトル |
-
en
The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic
|
| その他のタイトル |
-
en
Suppression of metastatic cancer by N116Y
|
| 作成者 |
|
| アクセス権 |
open access |
| 主題 |
-
Other
en
ras suppressor
-
Other
en
pancreatic cancer
-
Other
en
liver metastasis
-
NDC
491.69
|
| 内容注記 |
-
Abstract
en
In pancreatic cancer, the mutation of c-K-ras is a critical event of tumor growth and metastasis.1 We have previously demonstrated a dominant negative effect of N116Y on the growth of pancreatic cancer cells.2 To evaluate the potential of N116Y for suppressing the metastatic growth of pancreatic tumor cells, we made a replication-deficient recombinant N116Y adenovirus driven by the carcinoembryonic antigen (CEA) promoter (Ad CEA-N116Y). We demonstrated that the expression of N116Y, growth inhibition, and apoptotic death induction were all specific to pancreatic cancer cell lines (PCI-35 and PCI-43) that were promoter positive, whereas no growth retardation was observed in human embryonic pancreas-derived cell line 1C3D3 after Ad CEA-N116Y infection. We examined the effect of Ad CEA-N116Y on the metastatic growth of PCI-43 colonies in liver, which were generated by tumor injection into the spleen of nude mice. The results showed that Ad CEA-N116Y effectively reduced the number of metastatic colonies without any complication by injecting intrasplenically five days after tumor cell inoculation. Thus N116Y can selectively suppress the metastatic growth of pancreatic tumor cell by using the CEA promoter driven adenovirus vector indicating that N116Y gene therapy may be potentially useful for the treatment of pancreatic cancer patients with liver micrometastasis.
|
| 出版者 |
en
Nature Publishing Group
|
| 日付 |
|
| 言語 |
|
| 資源タイプ |
journal article |
| 出版タイプ |
AM |
| 資源識別子 |
HDL
http://hdl.handle.net/2115/717
|
| 関連 |
-
URI
http://www.nature.com/gt/index.html
|
| 収録誌情報 |
-
en
Gene Therapy
-
巻7
号6
開始ページ518
終了ページ526
|
| ファイル |
|
| コンテンツ更新日時 |
2023-07-26 |
